Camellino D, Dejaco C
Division of Rheumatology, Locomotor Apparatus Department, La Colletta Hospital, ASL3 Genovese, Arenzano (GE); Autoimmunology Lab, Department of Internal Medicine, University of Genova.
Reumatismo. 2018 Mar 27;70(1):59-66. doi: 10.4081/reumatismo.2018.1062.
Polymyalgia rheumatica (PMR) is the second most common inflammatory rheumatic disease in the elderly after rheumatoid arthritis. It is clinically characterised by pain and stiffness in the neck, proximal shoulder and hip girdle. Glucocorticoids (GCs) are the cornerstone of PMR treatment, but they are associated with potentially severe side effects. Among GC-sparing agents, methotrexate revealed a modest benefit in clinical trials, and recently, there have been promising reports from tocilizumab. In this review, we summarize the available evidence on the treatment of PMR and the possible role in the future of other agents under investigation.
风湿性多肌痛（PMR）是老年人中仅次于类风湿关节炎的第二常见炎性风湿性疾病。其临床特征为颈部、近端肩部和髋部带疼痛及僵硬。糖皮质激素（GCs）是PMR治疗的基石，但它们伴有潜在的严重副作用。在糖皮质激素节约药物中，甲氨蝶呤在临床试验中显示出一定益处，最近，托珠单抗也有了令人鼓舞的报告。在本综述中，我们总结了关于PMR治疗的现有证据以及其他正在研究的药物在未来可能发挥的作用。
